Brief: Mesoblast Expects Gross Revenue Of More Than $30.0 Mln From Sales Of Ryoncil For Quarter Ending Dec 31
25/11/2025 15:08
Nov 25 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST LTD - FOR QUARTER ENDING DECEMBER 31, 2025, EXPECTS GROSS REVENUE OF MORE THAN US$30.0 MILLION FROM SALES OF RYONCIL Source text: [ID:n0001345099-25-000101] Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M